— Know what they know.
Not Investment Advice
Also trades as: ACR.AX (ASX) · $vol 0M

ARUXF OTC

Acrux Limited
1W: +0.0% 1M: +0.0% 3M: -80.5% YTD: -79.7% 1Y: -93.4% 3Y: -89.0% 5Y: -97.5%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 44 · $1.3M mcap · 308M float · 0.0086% daily turnover · Short 71% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.3M
52W Range0.001-0.0504
Volume40,000
Avg Volume26,501
Beta0.97
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJohn Warmbrunn
Employees43
SectorHealthcare
IndustryBiotechnology
IPO Date2010-06-08
103-113, Stanley Street
West Melbourne, VIC 3003
AU
61 3 8379 0100
About Acrux Limited

Acrux Limited, alongside its affiliated entities, specializes in the global development and commercialization of generic and topical pharmaceutical products. The company's reach extends across international markets, including Australia, Europe, and the United States. A significant part of its offerings includes diverse testosterone therapies, available in various forms such as oral and buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels, all aimed at treating adult men with low or absent testosterone levels. Additionally, Acrux provides estradiol sprays, sold under the brand names Evamist and Lenzetto, specifically formulated for women experiencing hot flashes associated with menopause. The company, established in 1998, is headquartered in West Melbourne, Australia.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms